New Drugs and Treatment Targets in Psoriasis

Medicin og biovidenskab

• Adenosine A3 Receptor Agonists 44%
• Biological Products 49%
• Clinical Trials 16%
• Congresses 25%
• Injections 14%
• Interleukin-23 32%
• Janus Kinase Inhibitors 35%
• Pharmaceutical Preparations 42%
• Phosphodiesterase Inhibitors 30%
• Psoriasis 100%
• Registries 20%
• Safety 14%
• Th17 Cells 30%
• Therapeutics 16%
• Ustekinumab 37%